Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial

Hepatology

Volumn 31, Issue 3, 2000, Pages 730-736

  Fontana, Robert J ^a,j   Israel, Jonathan ^b   LeClair, Paula ^c   Banner, Barbara F ^c   Tortorelli, Kristina ^c   Grace, Norman ^d   Levine, Robert A ^e   Fiarman, Gale ^f,i   Thiim, Michael ^f,h   Tavill, Anthony S ^g   Bonkovsky, Herbert L ^c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^f LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

^g CASE WESTERN RESERVE UNIVERSITY   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ HARVARD PILGRIM HEALTH CARE   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; IRON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; IRON STORAGE; LIVER BIOPSY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

EID: 17544383347     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510310325     Document Type: Article

References (29)

1. Seeff LB. Natural history of hepatitis C. HEPATOLOGY 1997;26(Suppl):21S-28S.
2. Dusheiko G. Side effects of alpha Interferon in chronic hepatitis C. HEPATOLOGY 1997;26(Suppl):112S-122S.
3. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485-1492.
4. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, Shiffman ML, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998;339;1493-1499.
5. Davis GL, Lau JYN. Factors predictive of a beneficial response to therapy of hepatitis C. HEPATOLOGY 1997;26(Suppl):122S-127S.
6. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to Interferon therapy is influenced by the iron content of the liver. J Hepatol 1994:20:410-415.
7. Kaji K, Nakanuma Y, Sasaki M, Unoura M, Kobayashi K, Nonomura A. Hemosiderin deposition in portal endothelial cells: a novel hepatic hemosiderosis frequent in chronic viral hepatitis B and C. Hum Pathol 1995;26:1080-1085.
8. Olynyk J, Reddy R, DiBisceglie AM, Jeffers LJ, Parker Radick J, Schiff ER, Bacon BR. Hepatic iron concentration as a predictor of response to Interferon alpha therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109.
9. Fargion S, Fracanzani L, Sampietro M, Molteni V, Boldorini R, Mattioli, Cesana B, et al. Liver iron influences the response to interferon alpha therapy in chronic hepatitis C. Eur J Gastroenterol Hepatol 1997;9:497-503.
10. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. HEPATOLOGY 1997;25:759-768.
11. Bacon BR, Rebholz AE, Fried M, DiBisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon [Abstract]. HEPATOLOGY 1993;373:150A.
12. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomuar T, Sakomoto. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
13. Rubin RB, Barton A, Banner BF, Bonkovsky HL. Iron and chronic viral hepatitis: emerging evidence for an important interaction. Dig Dis 1995;13:223-238.
14. Sampietro PA, D'Alba M, Roffi L, Fargion S, Parma S, Nicoli C, Corbetta N, et al. Iron stores, response to interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
15. Van Thiel DH, Friedlander L, Molloy P, Kania RJ, Fagiuoli S, Wright HI, Gasbarriini A, et al. Retreatment of hepatitis C interferon non-responders with larger doses of IFN with and without phlebotomy. Hepatogastroenterology 1996;43:1557-1561.
16. Tsai NC-S, Zuckerman E, Han S-H, Goad K, Redeker AG, Hong TL. The effect of iron depletion on long-term response to interferon in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997:92:1831-1834.
17. Idilman R, Maria N de, Colantoni A, Dokmeci A, Van Thiel DH. Interferon treatment of cirrhotic patients with chronic hepatitis C. J Viral Hepat 1997;4:81-91.
18. Banner BF, Barton AL, Cable EE, Smith L, Bonkovsky HL. A detailed analysis of the Knodell score and other histologic parameters as predictors of response to interferon therapy in chronic hepatitis C. Mod Pathol 1995;8:232-238.
19. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995;103:419-424.
20. Ikura Y, Morimot H, Johmura H, Fukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. Am J Gastroenterol 1996;91:1367-1373.
21. Pockros PJ, Bain VG, Hunter EB, Conrad A, Balart A, Hollinger FB, Albert D, and the Consensus Interferon Study Group. A comparison of reverse transcription-polymerase chain reaction and branched DNA assays for hepatitis C virus RNA in patients receiving interferon treatment. J Viral Hepat 1999;6:145-150.
22. Stuvyer L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuveryswyn H, Maertens G. Typing of hepatitis C virus isolates and characterization of new genotypes. J GenVirol 1993;74:1093-1102.
23. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, DiBisceglie A, Tattrie C, Tortorelli K, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. HEPATOLOGY 1998;27:1661-1669.
24. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kieman, Wooman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. HEPATOLOGY 1981;1:431-435.
25. MacSween RNM, Anthony PP, Scheuer PJ. Pathology of the Liver. Edinburgh: Churchill Livingstone, 1987:185.
26. Lau JYN, Davis GL, Kniffen J, Qian K, Urdea MS, Chan CS, Mizokami M, et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993;341:1501-1504.
27. Tong MJ, Reddy R, Lee WM, Pockros PJ, Hoefs JC, Keeffe EB, Hollinger FB, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. HEPATOLOGY 1997;26:747-754.
28. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG, et al. Retreatment of chronic hepatitis C with consensus interferon. HEPATOLOGY 1998;27:1136-1143.
29. Reddy RK, Hoofnagle JH, Tong MJ, Lee WM, Pockros P, Heathcote EJ, Albert D, et al., for the Consensus Interferon Study Group. Racial differences in responses to therapy with interferon in chronic hepatitis C. HEPATOLOGY 1999;30:787-793.